Please ensure Javascript is enabled for purposes of website accessibility

COVID-19 Has U.S. Hospitals Scrambling to Stock Dialysis Supplies

By Cory Renauer – Apr 17, 2020 at 6:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coronavirus patients in intensive care units are using more dialysis fluids than anyone expected.

One unforeseen source of stress for intensive care units in COVID-19-positive hospitals has been the disease's association with kidney damage. In some New York hospitals, 30% of severely affected coronavirus patients also experience a loss of kidney function that requires lots of dialysis treatments to remedy.

Patients severely affected by COVID-19 usually need dialysis to filter their blood for much longer periods than they need to use a respirator for help breathing. Hospital systems that suddenly find themselves treating hundreds of coronavirus patients with dialysis are blasting through the usual amount of supplies kept on hand. 

Intensive care unit physician with a clipboard

Image source: Getty Images.

Unprecedented demand

Hospital employees aren't the only ones noticing rapidly diminishing dialysis supplies. Baxter (BAX -1.11%) manufacturers dialysis fluids, and the company's seeing a five-fold increase in demand at the moment. The FDA hasn't reported any shortages of dialysis equipment or supplies, although people that needed regular dialysis treatments before the COVID-19 pandemic could see disruptions at a local level.

Around one in seven adults in the U.S. is living with chronic kidney disease, and many of them need a regular supply of dialysis fluids. At the moment, Baxter is manufacturing new supplies at top speed to meet spiking demand in coronavirus hot spots without disrupting the usual supply.

Baxter and its peers might be able to keep supply chains from breaking down, but there isn't much that hospitals can do to boost a limited number of trained nursing staff available to administer time-consuming dialysis treatments. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Baxter International Inc. Stock Quote
Baxter International Inc.
BAX
$54.30 (-1.11%) $0.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.